Global Information
회사소개 | 문의 | 비교리스트

중동 호흡기 증후군(MERS) : 파이프라인 리뷰

Middle East Respiratory Syndrome (MERS) (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 410982
페이지 정보 영문 179 Pages 배송안내
가격
US $ 2,000 ₩ 2,543,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,086,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,630,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


중동 호흡기 증후군(MERS) : 파이프라인 리뷰 Middle East Respiratory Syndrome (MERS) (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 179 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

중동 호흡기 증후군(MERS)은 코로나 바이러스(MERS-CoV)에 기인한 바이러스성 호흡기질환입니다. 증상은 열, 기침, 헐떡임 등입니다. 다른 증상으로는 오심, 구토, 설사 등이 있습니다. 폐렴 증상이 잘 나타나는데, 신장 등의 기관을 손상시키기도 합니다. 치료에는 관절통이나 열 등의 증상을 완화시키는 것을 목적으로 링겔이나 약제를 이용합니다.

중동 호흡기 증후군(MERS: Middle East Respiratory Syndrome) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

서론

  • 조사 범위

중동 호흡기 증후군(MERS) 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 비교 분석

기업에서 개발중인 치료제

대학/연구기관에서 연구중인 치료제

파이프라인 제품 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발 참여 기업

  • Atriva Therapeutics GmbH
  • Autoimmune Technologies LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals Inc
  • Nanotherapeutics Inc
  • Novavax Inc
  • Phelix Therapeutics LLC
  • Planet Biotechnology Inc
  • Regeneron Pharmaceuticals Inc
  • Romark Laboratories LC

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

  • 3B-11
  • ATR-006
  • BNSP-333S1
  • CSW-1
  • Drugs to Inhibit Cathepsin L for Coronaviridae Infections
  • FBR-001
  • INO-4500
  • LCA-60
  • Middle East respiratory syndrome coronavirus vaccine
  • Middle East respiratory syndrome coronavirus vaccine
  • Middle East respiratory syndrome vaccine
  • Middle East respiratory syndrome vaccine
  • Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine
  • nitazoxanide
  • REGN-3048
  • REGN-3051
  • SAB-301

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.01.31

List of Tables

List of Tables

  • Number of Products under Development for Middle East Respiratory Syndrome (MERS), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Middle East Respiratory Syndrome (MERS) - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Middle East Respiratory Syndrome (MERS), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2021, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it causes injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 20, 19 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 11 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Middle East Respiratory Syndrome (MERS) - Overview
  • Middle East Respiratory Syndrome (MERS) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
  • Middle East Respiratory Syndrome (MERS) - Drug Profiles
  • Middle East Respiratory Syndrome (MERS) - Dormant Projects
  • Middle East Respiratory Syndrome (MERS) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q